Moderna raises 2026 revenue growth forecast to as much as 25%
TREE NEWS reports: Moderna on Thursday raised its full-year revenue outlook and said it expects sales to grow by as much as 25% in 2026, as the company works to offset declining demand for its COVID-19 vaccine. The biotech firm now projects 2025 revenue of $1.6 billion to $1.8 billion, up from a prior range of $1.5 billion to $1.7 billion. For 2026, Moderna expects revenue growth of 15% to 25%.
The upbeat guidance comes as Moderna continues to cut costs and streamline its pipeline. The company has been under pressure from falling COVID vaccine sales and has been investing heavily in its mRNA pipeline, including a personalized cancer vaccine being developed with Merck.
Cancer vaccine data is the real catalyst
While the raised outlook is a positive signal, investors are focused on what happens next with the company’s experimental cancer vaccine, mRNA-4157 (V940). Moderna and Merck are expected to report updated data from a Phase 2b trial in high-risk melanoma patients later this year. The vaccine is seen as a potential blockbuster and a key part of Moderna’s long-term growth story.
Analysts say the revenue guidance is encouraging but unlikely to move the stock significantly on its own. “The real driver will be the cancer vaccine data,” said one healthcare analyst. “If the data is strong, it could validate the entire mRNA platform beyond COVID.”
Market implications
Stocks: Moderna shares could see elevated volatility around the cancer vaccine data readout. A positive result could lift the stock and boost sentiment for other mRNA-focused biotechs. A disappointing result could weigh on the shares and raise questions about the company’s growth prospects.
Bonds: The news is unlikely to have a direct impact on fixed income markets, as it is company-specific. However, a strong biotech sector can support risk appetite in credit markets.
Crypto: No direct impact. Crypto markets are driven by macro and regulatory factors.
Commodities: No direct impact.
Currencies: No direct impact.
Key takeaways for investors
- Moderna’s raised revenue outlook is a positive sign, but the stock’s near-term direction hinges on cancer vaccine data.
- The company is diversifying beyond COVID, with mRNA-4157 as the most important near-term catalyst.
- Investors should watch for trial updates and any partnership developments with Merck.
- Biotech stocks are volatile; position sizing and risk management are crucial.
